entertainment -WSS

entertainment

author：hotspot 2025-10-02 00:18:11 - browse：27681

A caretaker speaks with an elderly Alzheimer's patient at a nursing home. — ALAIN JOCARD/AFP via Getty Images

For more than 30 years, Alzheimer’s researchers have thought of APOE4 as a major genetic risk factor for most cases of the devastating neurologic disease. But a new study published on Monday argues that this gene variant plays an even more important role than scientists had realized and causes a distinct form of Alzheimer’s.

Researchers analyzed data from more than 13,000 people, including nearly 800 APOE4 homozygotes, people who carry two copies of the gene variant. They found that nearly all of the homozygotes showed biological signs of Alzheimer’s in the brain, and they typically developed dementia and other symptoms, and died sooner, than people with Alzheimer’s who lack APOE4.

The research team also found that APOE4 homozygotes showed a predictable pattern of biomarker changes linked to Alzheimer’s, including a buildup of beta-amyloid and tau, a protein linked to neuron damage and death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

WSS

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Humana’s losses in Medicare Advantage tank its stock

Amylyx ALS drug fails large clinical trial

Headspace, Meta partner to launch VR meditation app for Quest

Humana’s losses in Medicare Advantage tank its stock

Former medical device CEO who sold dummy, plastic parts convicted of fraud

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

What does generative AI mean for health care? We asked experts

Humana’s losses in Medicare Advantage tank its stock

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Peter Hotez and the public health issue of online harassment

Reconstructing family trees of blood cells may help predict disease

In age of alternative facts, a scholarly course on calling out crap

Syphilis numbers in the United States reach record heights

Walensky prepares to leave CDC — and Congress — behind

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

focus

The Readout: Amylyx, Alumis, and Lundbeck drug updates

The Affordable Care Act has saved billions in health care costs

Air quality improving but still lags in Black, Hispanic communities

Readout Newsletter: The latest on Novavax, Merck, Bluebird

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

focus

entertainment

hotspot

focus